[Federal Register Volume 82, Number 230 (Friday, December 1, 2017)]
[Notices]
[Page 56968]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25899]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY: Assistant Secretary of Defense (Health Affairs), Department of 
Defense.

ACTION: Notice of Federal Advisory Committee meeting.

-----------------------------------------------------------------------

SUMMARY: The Department of Defense is publishing this notice to 
announce a Federal Advisory Committee meeting of the Uniform Formulary 
Beneficiary Advisory Panel (hereafter referred to as the Panel).

DATES: Open to the public on Thursday, January 4, 2018, from 9:00 a.m. 
to 12:00 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Captain Edward C. Norton, United 
States Navy, Designated Federal Official, Uniform Formulary Beneficiary 
Advisory Panel, 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 
22042-5101. Email Address: [email protected].

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act of 1972 (5 U.S.C., 
Appendix, as amended), the Government in the Sunshine Act of 1976 (5 
U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director of the Defense Health Agency, by 
the Pharmacy and Therapeutics Committee, regarding the Uniform 
Formulary.
    Meeting Agenda:

1. Sign-In
2. Welcome and Opening Remarks
3. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item)
    a. Weight Loss Agents
    b. Oncological Agents: Multiple Myeloma
    c. Prenatal Vitamins
4. Newly Approved Drugs Review
5. Pertinent Utilization Management Issues
6. Panel Discussions and Vote

    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 CFR 102-3.140 through 102-3.165, and the availability of space, this 
meeting is open to the public. Seating is limited and will be provided 
only to the first 220 people signing-in. All persons must sign-in 
legibly.
    Written Statements: Pursuant to 41 CFR 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel about its mission and/or the agenda to be 
addressed in this public meeting. Written statements should be 
submitted to the Panel's Designated Federal Officer (DFO). The DFO's 
contact information can be obtained in the FOR FURTHER INFORMATION 
CONTACT section.
    Written comments or statements must be received by the committee 
DFO at least five (5) business days prior to the meeting so that they 
may be made available to the Panel for its consideration prior to the 
meeting. The DFO will review all submitted written statements and 
provide copies to all the committee members.

    Dated: November 28, 2017.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2017-25899 Filed 11-30-17; 8:45 am]
 BILLING CODE 5001-06-P